|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
A06AH01
|
|
gptkbp:brand
|
gptkb:Relistor
|
|
gptkbp:CASNumber
|
119462-56-5
|
|
gptkbp:chemicalFormula
|
C21H26NO4+
|
|
gptkbp:contraindication
|
known or suspected gastrointestinal obstruction
|
|
gptkbp:developer
|
gptkb:Progenics_Pharmaceuticals
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:genericName
|
gptkb:methylnaltrexone
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Relistor
|
|
gptkbp:indication
|
treatment of opioid-induced constipation in adults with chronic non-cancer pain
treatment of opioid-induced constipation in adults with advanced illness
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Bausch_Health
|
|
gptkbp:mechanismOfAction
|
peripherally acting mu-opioid receptor antagonist
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
dizziness
flatulence
|
|
gptkbp:usedFor
|
opioid-induced constipation
|
|
gptkbp:bfsParent
|
gptkb:Bausch_Health_Companies
gptkb:Valeant_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|